<DOC>
	<DOCNO>NCT02117453</DOCNO>
	<brief_summary>The purpose study ass whether rosuvastatin could reduce subclinical marker atherosclerosis incidence major cardiovascular event patient primary necrotizing vasculitides .</brief_summary>
	<brief_title>Multicenter , Prospective , Randomized , Controlled , Double-blind Trial Impact Rosuvastatin Subclinical Markers Atherosclerosis Patients With Primary Necrotizing Vasculitides</brief_title>
	<detailed_description>Previous study demonstrate presence subclinical atherosclerosis patient ANCA-associated systemic necrotizing vasculitis . Since statin low level inflammatory protein cholesterol , hypothesize people ANCA-associated systemic necrotizing vasculitis without indication statin treatment accord recommandations might benefit statin treatment .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patient &gt; 18 year . ANCAassociated vasculitis : granulomatosis polyangiitis ( GPA ) , microscopic polyangiitis ( MPA ) eosinophilic granulomatosis polyangiitis ( EGPA , ChurgStrauss syndrome ) . Patients fulfill Chapel Hill Consensus Criteria American College Rheumatology criterion , remission vasculitis . Patients remission vasculitis induction therapy ( first flare relapse ) , include corticosteroid associate immunosuppressive agent accord Good Clinical Practice treatment vasculitis , 6 month 10 year begin induction therapy . Patients inform sign consent Other systemic vasculitis . Secondary vasculitis ( paraneoplastic infectious ) . Patient active vasculitis induction therapy , require salvage therapy . Inability sign inform consent . Inability take experimental treatment . Hypersensitivity rosuvastatin excipients . Pregnancy . Chronic HCV , HBV and/or HIV infection . Patient receive statin hypolipemic agent . Patient require treatment statin accord Afssaps recommandations publish 2005 primary secondary prevention . Subclinical atherosclerosis confers high cardiovascular risk patient randomization : Carotid stenosis great 50 % diameter Ectasia abdominal aorta Intimamedia thickening great 1.2 mm Diffuse atherosclerosis lesion Heterogeneous hypoechoic prominent plaque great 2 mm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ANCA vasculitis</keyword>
	<keyword>Statin</keyword>
	<keyword>Subclinical marker atherosclerosis</keyword>
	<keyword>Cardiovascular event</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Stroke</keyword>
	<keyword>Arterial revascularization</keyword>
	<keyword>Unstable angina</keyword>
	<keyword>Death</keyword>
</DOC>